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ABSTRACT
The metabolic syndrome, by definition, is not a disease but is a clustering of individual 
metabolic risk factors including abdominal obesity, hyperglycemia, hypertriglyceridemia, 
hypertension, and low high-density lipoprotein cholesterol levels. These risk factors could 
dramatically increase the prevalence of type 2 diabetes and cardiovascular disease. The 
reported prevalence of the metabolic syndrome varies, greatly depending on the definition 
used, gender, age, socioeconomic status, and the ethnic background of study cohorts. 
Clinical and epidemiological studies have clearly demonstrated that the metabolic syndrome 
starts with central obesity. Because the prevalence of obesity has doubly increased worldwide 
over the past 30 years, the prevalence of the metabolic syndrome has markedly boosted 
in parallel. Therefore, obesity has been recognized as the leading cause for the metabolic 
syndrome since it is strongly associated with all metabolic risk factors. High prevalence of 
the metabolic syndrome is not unique to the USA and Europe and it is also increasing in most 
Asian countries. Insulin resistance has elucidated most, if not all, of the pathophysiology 
of the metabolic syndrome because it contributes to hyperglycemia. Furthermore, a major 
contributor to the development of insulin resistance is an overabundance of circulating fatty 
acids. Plasma fatty acids are derived mainly from the triglycerides stored in adipose tissues, 
which are released through the action of the cyclic AMP-dependent enzyme, hormone 
sensitive lipase. This review summarizes the latest concepts in the definition, pathogenesis, 
pathophysiology, and diagnosis of the metabolic syndrome, as well as its preventive measures 
and therapeutic strategies in children and adolescents.
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INTRODUCTION
The metabolic syndrome is defined as a clustering of metabolic abnormalities that 
include central obesity, insulin resistance, hypertriglyceridemia, hypercholesterolemia, 
hypertension, and reduced high-density lipoprotein (HDL)-cholesterol concentrations 
[1-4]. It is also associated with other comorbidities including the proinflammatory state, 
prothrombotic state, nonalcoholic fatty liver disease (NAFLD), cholesterol gallstone 
disease, and reproductive disorders [5-16]. The metabolic syndrome has been considered 
to be one of the most risk factors for the epidemic of type 2 diabetes and cardiovascular 
disease in the 21 century [17-22]. Furthermore, it could be mainly caused by inactive lifestyle, 
overconsumption of food, and the resulting abdominal obesity. However, it has been 
recognized that the metabolic syndrome is not a disease but is a common complex entity 
that emerges as a worldwide epidemic and major public health concern with a prevalence 
rate of approximately 25% in American adults [23-26]. Moreover, the prevalence of the 
metabolic syndrome is increasing not only in the USA and Europe, but also in Asian countries 
such as China, India, and South Korea [27-41]. Most studies have found that the metabolic 
syndrome is associated with an approximate doubling of cardiovascular disease risk and a 
5-fold increased risk for type 2 diabetes. Although it is unclear whether there is a unifying 
pathogenic mechanism that could decipher the pathophysiology of the metabolic syndrome, 
it is highly likely that abdominal obesity and insulin resistance could play a central role 
in promoting the development of the metabolic syndrome [42-44]. Therefore, lifestyle 
modification and weight loss should be considered to be the first step for preventing or 
treating the metabolic syndrome [45-47]. In addition, other cardiac risk factors should be 
actively managed in individuals with the metabolic syndrome [48].
Although there are many different definitions of the metabolic syndrome, almost all the 
metabolic abnormalities include central obesity, hypercholesterolemia, reduced HDL-
cholesterol levels, hypertension, and elevated plasma triglycerides, with insulin resistance 
as the potential uniting pathogenic factor [49]. The importance of the metabolic syndrome 
is not just related to its high prevalence rate worldwide but also because it could help predict 
the development of type 2 diabetes and cardiovascular disease [50-52]. Both NAFLD and 
cholesterol gallstone disease are now recognized to be the two major hepatic components of 
the metabolic syndrome, a kind of “fellow travelers” [6,53-55]. Moreover, high triglyceride 
and cholesterol concentrations in the liver together with other risk components, particularly 
insulin resistance, elevated plasma fatty acid concentrations, and diabetes, are the major risk 
factors for the development of nonalcoholic steatohepatitis (NASH), the most severe form 
of NAFLD [56-59]. However, the importance of the metabolic syndrome lies not in a specific 
definition but rather in its causative role and association with the worldwide epidemics of 
diabetes, cardiovascular disease, NAFLD, and NASH. According to the Guidelines of the 
National Cholesterol Education Program (NCEP) expert panel on the detection, evaluation 
and treatment of high blood cholesterol in adults (adult treatment panel III) (ATPIII), the 
main goal of identifying patients with the metabolic syndrome is to find individuals at high 
risk of cardiovascular disease that extends beyond low-density lipoprotein (LDL)-cholesterol 
levels and is highly obesity-related morbidity and mortality [60].
Similar to adults, overweight and obesity in children and adolescents have become major 
public health issues as their prevalent rates have substantially increased not only in the 
USA and European countries, but also in Asian countries during the past three decades 
[61-68]. Based on the definition of the metabolic syndrome for adults, some modified 
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definitions of this syndrome for children and adolescents have been proposed over the past 
13 years; however, no unified definition has been proposed to assess risk or outcomes of 
the metabolic syndrome specially in pubertal subjects [69]. Obviously, a simple easy-to-use 
clinical definition is strongly needed to identify the metabolic syndrome in young people 
globally. Because obesity is associated with increased risk of cardiovascular disease and type 
2 diabetes, which may persist from childhood and adolescence into young adulthood [70-72], 
it is important to make early identification of children and adolescents who are at high risk of 
developing the metabolic syndrome. Therefore, it would be possible to give early preventive 
measures, including lifestyle modification, to these young people to halt the development of 
the metabolic abnormalities. In this review, we summarize recent advances in the definition, 
pathogenesis, pathophysiology, and diagnosis of the metabolic syndrome, as well as its 
prevention and treatment interventions in children and adolescents.
DEFINITION AND CLINICAL DIAGNOSIS
Although the term, the metabolic syndrome, has become widely used since the 1990s, it 
is recently that the concept of “clustering” metabolic disorders and cardiovascular disease 
risk factors is intensively discussed in the literature [73-77]. In 1923, Kylin [78] first reported 
a relationship between hypertension, hyperglycemia, and gout in adult patients. In 1978, 
Phillips [79] found the coexistence of impaired glucose metabolism with hyperinsulinemia, 
hyperlipidemia, and hypertension, thus increasing the risk of developing cardiovascular 
disease. In 1980, Albrink [80] reported a relationship between obesity, hypertriglyceridemia, 
and hypertension. In 1988, Reaven [81] described a clustering of the metabolic abnormalities 
with insulin resistance as the central pathophysiological feature and used the term, the 
syndrome X, to depict the potential relationship between insulin resistance, hypertension, 
type 2 diabetes, and cardiovascular disease. In addition, the syndrome X and other terms, 
such as the deadly quartet and the insulin resistance syndrome, have been largely used in the 
literature to describe the clustering of cardiovascular and metabolic risk factors for several 
decades [82-85]. However, the metabolic syndrome is most widely used for describing the 
metabolically associated disorders including obesity, insulin resistance, type 2 diabetes, 
hypertension, dyslipidemia, cardiovascular disease, NAFLD, NASH, and cholesterol gallstone 
disease [1,5,6,11,86-89].
Notably, many different definitions have been proposed to describe the metabolic syndrome 
in adults. In general, the metabolic syndrome is defined as a cluster of risk factors for 
cardiovascular disease and type 2 diabetes, including visceral obesity, dyslipidemia, impaired 
glucose tolerance, and hypertension. In 1998, the World Health Organization (WHO) was 
the first to propose a definition and diagnostic criteria [90], in which insulin resistance is 
considered to be the major pathogenic factor underlying the metabolic syndrome. However, 
the WHO definition has been criticized because of these weaknesses: (i) it is difficult to use 
the clamp technique to analyze insulin resistance and apply it to large-scale epidemiological 
surveys; (ii) it is not a precise method to use the ratio of waist to hip to measure abdominal 
obesity; and (iii) it is unclear about the relationship between insulin resistance and 
microalbuminuria [90].
Subsequently, the European Group for the Study of Insulin Resistance (EGIR) used fasting 
plasma glucose and insulin levels instead of the insulin clamp technique to define insulin 
sensitivity and proposed a new criterion for non-diabetic patients based on these parameters 
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[91,92]. In addition, the EGIR definition used the waist circumference, but not the ratio 
of waist to hip, to measure abdominal obesity. This significantly promoted wide-ranging 
epidemiological surveys.
In 2001, the NCEP:ATPIII proposed a new criterion to define the metabolic syndrome in 
adults, which worked as part of the educational program for the prevention of cardiovascular 
disease [93]. The NCEP:ATPIII definition did not list insulin resistance as a component. 
In contrast, it made all five components equally important, which greatly facilitates the 
diagnosis of the metabolic syndrome in clinical practice. Using the NCEP:ATPIII guidelines, 
the diagnosis of the metabolic syndrome requires the presence of at least three of the five 
components [93]. In general, the NCEP:ATPIII and the WHO criteria identify the same 
prevalence of the metabolic syndrome in adult patients, but the NCEP:ATPIII definition 
may be superior in identifying patients at increased risk of cardiovascular disease and for 
predicting type 2 diabetes. Nevertheless, these existing criteria for diagnosing the metabolic 
syndrome are less accurate in predicting clinical endpoints compared to other established 
models such as the Framingham risk score of cardiovascular disease. In addition, the 
American Association of Clinical Endocrinologists proposed a new criterion with a focus on 
insulin resistance and an exclusion of patients with type 2 diabetes.
Because of the use of different criteria for defining the metabolic syndrome in adults, 
the prevalence rates collected from epidemiological surveys vary greatly from country to 
country, as well as from region to region even in the same country. Thus, it is quite difficult 
to compare the reported prevalence rates of the metabolic syndrome around the world, 
as well as the data between studies due to these different diagnostic criteria. In 2005, the 
International Diabetes Federation (IDF) proposed a unifying definition that emphasizes 
the importance of central obesity and has it as a necessary condition to diagnose the 
metabolic syndrome [94,95]. In other words, the diagnosis of the metabolic syndrome 
requires central obesity plus two additional components. It should point out that the IDF 
criteria do not emphasize insulin resistance, but instead focus on fasting plasma glucose 
levels. In addition, a new set of criteria with ethnic/racial specific cutoffs were defined. For 
example, the guideline for measuring waist circumference was proposed and the ranges of 
waist circumference were specified for different ethnic/racial groups. In 2007, harmonizing 
the definition of the metabolic syndrome was proposed by comparison of the criteria of the 
NCEP:ATPIII and the IDF criteria in American and European populations [96]. In 2009, 
this harmonized definition for the metabolic syndrome was revised, which reached an 
agreement: (i) there should not be an obligatory component, but waist measurement would 
continue to be a useful preliminary screening tool; (ii) three abnormal findings out of 5 
would qualify a person for the metabolic syndrome; (iii) a single set of cut points would be 
used for all components except waist circumference, for which further work is required; and 
(iv) in the interim, national or regional cut points for waist circumference can be used [97]. 
Nevertheless, clinical practice and epidemiological investigations strongly demand a simple 
easy-to-use unifying definition of the metabolic syndrome.
For children and adolescents, the IDF Task Force on the Epidemiology and Prevention of 
Diabetes set a practical clinical criterion for the diagnosis of the metabolic syndrome in 2007 
[98,99]. Based on a modification of previous adult standards, the IDF has promoted a new 
criterion for the diagnosis of the metabolic syndrome mainly for children and adolescents 
between the ages of 10 and 16 years [98,99], as shown in Table 1. The definition of the 
metabolic syndrome in this age group is central obesity (≥90th percentile) plus the presence 
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of two or more other components (Fig. 1), including hypertriglyceridemia (≥1.7 mmoL/L; ≥150 
mg/dL), high blood glucose (≥5.6 mmoL/L; ≥100 mg/dL), high blood pressure (≥130 mmHg 
systolic or ≥85 mmHg diastolic), or low HDL-cholesterol levels (≤1.03 mmoL/L; ≤40 mg/dL). To 
date, the available data, however, were not sufficient to make a recommendation for children 
aged <6 years. For children aged between 6 and 10 years, as the metabolic syndrome cannot be 
diagnosed, they should be strongly recommended weight loss, especially those with abdominal 
obesity. For adolescents aged 16 years or older, the adult criteria could be used.
In 2014, a new criterion for defining the metabolic syndrome in prepubertal children was 
proposed by the identification and prevention of dietary- and lifestyle-induced health effects 
in children and infants (IDEFICS) study [100], which addressed the limitations of previous 
definitions in children and the need for early diagnosis in young people. Using reference 
values from the study of 18,745 children in eight European countries, the IDEFICS study 
set up the age-specific and sex-specific (and height-specific in the case of blood pressure) 
percentiles to identify cutoffs for the components of the metabolic syndrome in children 
at the age of 2-11 years [100]. However, the proposed cutoffs were based on a statistical 
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Table 1. The IDF definition of the at-risk group and the metabolic syndrome in children and adolescents (2007)
Age group (yr) Obesity (WC) Triglycerides HDL-C Blood pressure Plasma glucose
6–<10* ≥90th percentile
10–<16 ≥90th percentile or adult 
cut-off if lower
≥1.7 mmoL/L (≥150 mg/dL) <1.03 mmoL/L (<40 mg/dL) Systolic BP ≥130 or  
Diastolic BP ≥85 mmHg
FPG ≥5.6 mmoL/L  
(100 mg/dL)‡ or known 
T2DM
16+ (adult criteria) WC ≥94 cm for Europid 
males and ≥80 cm for 
Europid females, with 
ethnic-specific values for 
other groups†)
≥1.7 mmoL/L (≥150 mg/dL)  
or specific treatment for 
high triglycerides
<1.03 mmoL/L (<40 mg/dL) 
in males and <1.29 mmoL/L 
(<50 mg/dL) in females, or 
specific treatment for low 
HDL
Systolic BP ≥130 or  
diastolic BP ≥85 mmHg or 
treatment of previously 
diagnosed hypertension
FPG ≥5.6 mmoL/L  
(100 mg/dL)‡ or known 
T2DM
IDF: International Diabetes Federation, WC: waist circumference, HDL-C: high-density lipoprotein cholesterol, BP: blood pressure, FPG: fasting plasma glucose; 
T2DM: type 2 diabetes mellitus.
*The metabolic syndrome cannot be diagnosed, but further measurements should be made if there is a family history of the metabolic syndrome, type 2 
diabetes, dyslipidemia, cardiovascular disease, hypertension, and/or obesity.
†For those of South and South-East Asian, Japanese, and ethnic South and Central American origin, the cutoffs should be ≥90 cm for men, and ≥80 cm for 
women. The IDF Consensus Group recognize that there are ethnic, gender and age differences, but research is still needed on outcomes to establish risk.
‡For clinical purposes, but not for diagnosing the metabolic syndrome, if fasting plasma glucose is 5.6–6.9 mmoL/L (100–125 mg/dL) and it is not known to have 
diabetes, an oral glucose tolerance test should be performed.













Fig. 1. Criteria for clinical diagnosis of the metabolic syndrome in childhood and adolescence. The definition of the 
metabolic syndrome in this age group is central obesity plus the presence of two or more than two components. 
HDL-C: high-density lipoprotein cholesterol.
definition and these did not allow to quantify the risk of subsequent diseases such as type 2 
diabetes and cardiovascular disease.
Obviously, the diagnostic standards for adults cannot be simply used in children and 
adolescents, particularly in toddlers and even younger children, because of significant 
changes in body size and continuous growth and development with age. Furthermore, 
puberty has a drastic effect on fat redistribution in the body, leading to an enhanced insulin 
sensitivity in the liver, adipose tissues, and muscle, as well as an increased insulin secretion 
by the pancreatic β cells. In other words, compared to that in adults, insulin sensitivity is 
lower by 25 to 50% during childhood and returns to normal after pubertal development. 
Growth and developmental changes with age are also associated with physiological 
adjustments in blood pressure, plasma lipid levels, and energy metabolism, as well as glucose 
and lipid metabolism in the liver and adipose tissues. All these factors make it difficult to 
develop a precise definition for the diagnosis of the metabolic syndrome in young people 
with different ages, different ethnic/racial groups, and genders. In particular, because of 
the lack of reference values for some of the components of metabolic syndrome in children 
and adolescents, a consensus definition is not proposed easily. Notably, over the past 30 
years, there is a significant increase in the prevalent rate of obesity-related complications 
in children and adolescents [101-108]. This high prevalence underscores the urgent need to 
develop a new definition for the diagnosis of the metabolic syndrome in young people. In 
addition, further research is imperative to identify biomarkers of the metabolic syndrome 
in early childhood. Long-term studies are also needed in children and adolescents with 
obesity, with a particular focus on intervention strategies. This will allow early diagnosis 
and timely action, including lifestyle modification and pharmaceutical intervention, to halt 
the development of metabolic abnormalities, thereby preventing long-term metabolic and 
cardiovascular consequences in children and adolescents [109-111].Obviously, the diagnostic 
standards for adults cannot be simply used in children and adolescents, particularly in 
toddlers and even younger children, because of significant changes in body size and 
continuous growth and development with age. Furthermore, puberty has a drastic effect on 
fat redistribution in the body, leading to an enhanced insulin sensitivity in the liver, adipose 
tissues, and muscle, as well as an increased insulin secretion by the pancreatic β cells. In 
other words, compared to that in adults, insulin sensitivity is lower by 25 to 50% during 
childhood and returns to normal after pubertal development. Growth and developmental 
changes with age are also associated with physiological adjustments in blood pressure, 
plasma lipid levels, and energy metabolism, as well as glucose and lipid metabolism in the 
liver and adipose tissues. All these factors make it difficult to develop a precise definition 
for the diagnosis of the metabolic syndrome in young people with different ages, different 
ethnic/racial groups, and genders. In particular, because of the lack of reference values for 
some of the components of metabolic syndrome in children and adolescents, a consensus 
definition is not proposed easily. Notably, over the past 30 years, there is a significant 
increase in the prevalent rate of obesity-related complications in children and adolescents 
[101-108]. This high prevalence underscores the urgent need to develop a new definition 
for the diagnosis of the metabolic syndrome in young people. In addition, further research 
is imperative to identify biomarkers of the metabolic syndrome in early childhood. Long-
term studies are also needed in children and adolescents with obesity, with a particular 
focus on intervention strategies. This will allow early diagnosis and timely action, including 
lifestyle modification and pharmaceutical intervention, to halt the development of metabolic 
abnormalities, thereby preventing long-term metabolic and cardiovascular consequences in 
children and adolescents [109-111].
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EPIDEMIOLOGY AND PREVALENCE
The prevalence rates of the metabolic syndrome have markedly increased not only in adults, 
but also in children and adolescents throughout the world over the past 30 years [112-115]. 
However, there is a striking difference in the prevalence rates of the metabolic syndrome in 
the USA and other countries, greatly depending on which definition is used to categorize 
individuals and determine inclusion and exclusion (Table 2) [62,63,65,98,438-441], as well 
as to analyze the composition of the population, e.g., gender, age, race, and ethnicity [116-
118]. Additionally, lifestyle habits and socioeconomic status have a marked impact on the 
prevalence rates of the metabolic syndrome across gender, age, and race/ethnicity cohorts, as 
found by some epidemiological studies [112,119,120].
The WHO and the NCEP:ATPIII definitions for adults are basically similar in the diagnostic 
criteria on obesity, hypertension, and dyslipidemia [90,93]. However, type 2 diabetes, insulin 
resistance, and/or impaired glucose tolerance are a prerequisite for the WHO definition, 
making the criterion relatively more restrictive [90]. The exclusion of patients with type 2 
diabetes from the EGIR definition also makes its definition less inclusive [91,92]. In contrast, 
the IDF definition has central obesity as its prerequisite and this may make it relatively 
less restrictive comparted to the NCEP:ATPIII definition [94,95]. Prevalence became more 
inclusive after the original NCEP:ATPIII criteria were revised to include the cutoff for 
impaired fasting glucose, i.e., ≤100 mg/dL vs. 110 mg/dL, as recommended by the 2003 
criteria of the American Diabetes Association [121]. Because the vast majority of diabetic 
patients meet the minimum criteria for the diagnosis of the metabolic syndrome, inclusion 
or exclusion of patients with type 2 diabetes has a marked impact on the prevalence rates 
while using the WHO or the NCEP:ATPIII definitions for epidemiological studies. In general, 
higher prevalence may be estimated using the IDF definition compared to the NCEP:ATPIII 
definition, as well as using the revised NCEP:ATPIII definition compared to the original 
one. Moreover, there is a difference in the age-adjusted prevalence rates among the various 
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Table 2. Different definitions of the metabolic syndrome in children and adolescents [62,63,65,98,438-441]
Cook (2003) Cruz (2004) Weiss (2004) de Ferranti (2004) Ford (2005) Viner (2005) IDF (2007) IDEFICS (2012)








Fasting glucose ≥6.1 
mmoL/L  
(≥110 mg/dL)
Fasting glucose ≥110 
mg/dL (additional 
analysis with ≥100 
mg/dL)
Hyperinsulinemia 
≥104.2 pmoL/L (15 
mU/L) or impaired 
fasting glucose ≥6.11 
mmoL/L (110 mg/dL)
Impaired fasting 









and sex specific, 
NHANES III)
WC ≥90th 
percentile (age, sex 
and race specific, 
NHANES III)
BMI–Z score ≥2.0 
(age and sex 
specific)




BMI ≥95th percentile WC ≥90th percentile WC ≥90th 
percentile
Triglycerides 




and sex specific, 
NHANES III)
Triglycerides >95th 
percentile (age, sex 



















and sex specific, 
NHANES III)
HDL-C <5th 
percentile (age, sex 
and race specific, 
NGHS)
HDL-C <1.3 mmoL/L  
(<50 mg/dL)
HDL-C ≤40 mg/
dL (all ages/sexes, 
NCEP)
HDL-C <0.91 mmoL/L 
(35 mg/dL) or high 
total cholesterol 
≥95th percentile










(age, sex and height 
specific, NHBPEP)
Blood pressure >95th 
percentile (age, sex 






(age, sex and height 
specific, NHBPEP)
SBP ≥95th percentile SBP ≥17.3 kPa (130 
mmHg) or DBP ≥11.3 
kPa (85 mm Hg)
SBP ≥90th 
percentile or DBP 
≥90th percentile
IDF: International Diabetes Federation, IDEFICS: identification and prevention of dietary- and lifestyle-induced health effects in children and infants, WC: waist 
circumference, NHANES: National Health and Nutrition Examination Survey, NCEP: National Cholesterol Education Program, HDL-C: high-density lipoprotein 
cholesterol, NHBPEP: National High Blood Pressure Education Program, ADA: American Diabetes Association, BMI: body mass index, NGHS: National Growth and 
Health Study, SBP: systolic blood pressure, DBP: diastolic blood pressure, HOMA: homeostatic model assessment.
definitions of metabolic syndrome [122-124]. It is worth noting that definition-related 
differences in prevalence are not consistent among countries, whereas these differences may 
be attributed, in part, to the race-specific waist circumference guidelines.
Although one definition with cutoffs specific for gender and ethnic origin could be 
appropriate for at-risk adults, using such definition for children and adolescents is 
problematic because lipid concentrations in the liver, adipose tissues, and plasma, as well as 
anthropometric variables, blood pressure, and insulin sensitivity change dramatically with 
age and pubertal development [124]. Furthermore, for children aged 10 years or older, the 
diagnosis of the metabolic syndrome is often made by abdominal obesity plus the presence of 
two or more other clinical features, i.e., hyperglycemia, hypertriglyceridemia, hypertension, 
or low plasma HDL-cholesterol levels (Table 3) [100]. Despite this, a major problem with 
the diagnosis of the metabolic syndrome in children and adolescents is that no established 
criteria for this young population are available to date. The uniqueness of pubertal growth 
patterns, effects of hormonal changes of puberty on insulin sensitivity and lipid profile, 
redistribution of adipose tissues in the body, and the impact of ethnic background on 
components of the metabolic syndrome make such criteria difficult to establish for children 
and adolescents [34,64,125-152].
As shown by epidemiological investigations, the presence of the metabolic syndrome in 
children and adolescents could be an important predictor of future risk for type 2 diabetes 
and cardiovascular disease in adulthood [63,64,153,154]. The results from the Bogalusa Heart 
Study suggested that cardiovascular risk factors present in childhood could be predictive of 
coronary artery disease in adulthood [155-162]. This study pointed out that plasma LDL-
cholesterol concentrations and BMI determined in childhood could be used to predict 
carotid intima-media thickness in young adults. In addition, visceral obesity is the major 
determinant of insulin resistance in children and adolescents [163-170], which increases the 
risk not only for the metabolic syndrome in young people, but also for the development of 
cardiovascular disease and type 2 diabetes in adulthood [124].
Table 4 [15] shows the recommended waist circumference thresholds for abdominal obesity 
in adults by different organizations. Although numerous variables have been used to define 
obese children, waist circumference is an important predictor that is independent of insulin 
resistance, plasma lipid levels, and blood pressure in young people [171-177], which is 
consistent with the situation in adults [178-182]. Even if children and adolescents are obese 
and have similar BMI, insulin sensitivity is lower in those with large amounts of visceral 
adipose tissues compared to those with small amounts [183-187]. For the new IDF criteria, 
it is critical to use waist circumference to define central obesity in children and adolescents 
[94,95]. Moreover, percentiles, but not absolute values, of waist circumference are used by 
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Table 3. The IDEFICS definition of the metabolic syndrome in children aged 2–11 years (2014)
· Obesity: ≥90th percentile as assessed by waist circumference
· Triglycerides: ≥90th percentile
· HDL cholesterol: ≤10th percentile
· Blood pressure: systolic ≥90th percentile or diastolic ≥90th percentile
·  Glucose: insulin ≥90th percentile or fasting glucose ≥90th percentile, according to homeostasis model 
assessment
Each category counts as one risk criterion.
IDEFICS: identification and prevention of dietary- and lifestyle-induced health effects in children and infants, 
HDL: high-density lipoprotein.
Modified and reproduced with permission from reference [100].
the new IDF definition to compensate for variation in child development and ethnic origin 
[94,95]. Children and adolescents with a waist circumference higher than the 90th percentile 
have multiple risk factors for cardiovascular disease compared to those with lower one. Many 
studies have used the 90th percentile as a cutoff for waist circumference in young people. As 
a result, the concept of using percentiles of waist circumference, which is specific to ethnic 
origin, is becoming increasingly acceptable for clinical studies [188-193]. In addition, the 
90th percentile as a cutoff for waist circumference has been used as the essential standard for 
the diagnosis of the metabolic syndrome in children and adolescents [94,95,194].
The reported prevalence rates of the metabolic syndrome in young people vary greatly 
depending on the age and population studied and the definition used. Because it is more 
difficult to assess the prevalence rates of the metabolic syndrome in children and adolescents 
compared to adults, this has greatly prompted the development of new simple-to-use 
definitions. Many new definitions of the metabolic syndrome in young people builds on 
previous studies that used the modified adult criteria to investigate prevalence in children 
and adolescents [195-200]. A study using the modified NCEP:ATPIII criteria found that the 
prevalence of metabolic syndrome in adolescents is 12% [98]. The National Health and 
Nutrition Examination Survey III (NHANES) reported approximately 10% of children and 
adolescents aged 12–19 years suffer from the metabolic syndrome [62]. As estimated by 
population-weighted studies, it is highly likely that more than 2 million American youngsters 
suffer from the phenotypes of the metabolic syndrome [61-63]. The metabolic syndrome is 
most frequent in obese adolescents, with a prevalence of 32.1%, compared with only 7.1% 
in overweight adolescents [65,201]. Because of the increasing prevalence of overweight and 
obesity in children and adolescents, as well as the compelling relationship between obesity 
and the metabolic syndrome, it is well understood that the prevalence rates of the metabolic 
syndrome have augmented in American youngsters over the past 30 years.
In addition, there are racial/ethnic differences in the prevalence rates of the metabolic 
syndrome, as well as of individual components of the metabolic syndrome in children 
and adolescents. Using the 1986–1994 NHANES data as analyzed by the modified 
NCEP:ATPIII criteria, the overall prevalence rates of the metabolic syndrome in 2,430 
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Table 4. Recommended waist circumference thresholds for abdominal obesity in adults by different organizations (2009)
Population Organization Recommended waist circumference threshold for abdominal obesity
Men Women
Europid IDF ≥94 cm ≥80 cm
Caucasian WHO ≥94 cm (increased risk) ≥80 cm (increased risk)
≥102 cm (still higher risk) ≥88 cm (still higher risk)
United States AHA/NHLBI (ATP III)* ≥102 cm ≥88 cm
Canada Health Canada ≥102 cm ≥88 cm
European European Cardiovascular Societies ≥102 cm ≥88 cm
Asian (including Japanese) IDF ≥90 cm ≥80 cm
Asian WHO ≥90 cm ≥80 cm
Japanese Japanese Obesity Society ≥85 cm ≥90 cm
China Cooperative Task Force ≥85 cm ≥80 cm
Middle East, Mediterranean IDF ≥94 cm ≥80 cm
Sub-Saharan African IDF ≥94 cm ≥80 cm
Ethnic Central and South American IDF ≥90 cm ≥80 cm
IDF: International Diabetes Federation, WHO: World Health Organization, NHLBI: National Heart, Lung, and Blood Institute, ATPIII: the adult treatment panel III.
*The guidelines of the American Heart Association and the National Heart, Lung, and Blood Institute for the metabolic syndrome recognize an increased risk 
for cardiovascular disease and diabetes at waist-circumference thresholds of ≥94 cm in men and ≥80 cm in women and identify these as optional cut points for 
individuals or populations with increased insulin resistance.
Modified and reproduced with permission from reference [15].
American adolescents are 4.2%, with 6.1% being boys and 2.1% being girls, respectively 
[62,71,202,203]. Among obese and overweight adolescents, the prevalence rates of the 
metabolic syndrome are 28.7% and 6.8%, respectively [62,71,202,203]. Similar to adults, the 
prevalence of individual components of the metabolic syndrome differed by race/ethnicity, 
e.g., the prevalence of hypertension is higher in African American adolescents compared to 
that in young non-Hispanic Caucasians or Mexican Americans. In contrast, the prevalence of 
hypertriglyceridemia and low plasma HDL-cholesterol concentrations is lower in the former 
than in the latter [204-213].
PATHOPHYSIOLOGY
Clinical and epidemiological studies have clearly demonstrated that obesity is often 
associated with many metabolic abnormalities including insulin resistance, impaired glucose 
tolerance, hypertension, hypercholesterolemia, and hypertriglyceridemia [214], as shown in 
Fig. 2. The cluster of these metabolic abnormalities is defined as the metabolic syndrome, 
a state associated with increased prevalence of several metabolic diseases such as type 2 
diabetes and cardiovascular disease, and all-cause mortality not only during adulthood, but 
also in children and adolescents [215]. The prevalence rates of obesity in adolescents (≥95th 
percentile of BMI for age) have dramatically increased from 15 to 37% over the last 30 years 
[107,216-220]. There is a risk of 50 to 77% for obese adolescents to become obese adults 
[221-223]. If parents are obese, this risk can increase to 80% for obese adolescents [224]. 
In addition, obese children and adolescents are at high risk of developing obesity-related 
complications and have shown an increased risk of adult morbidity and mortality [225-227].
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Fig. 2. Obesity and insulin resistance play a key role in the pathogenesis of the metabolic syndrome in childhood 
and adolescence. 
Ch GS: cholesterol gallstones, NAFLD: nonalcoholic fatty liver disease.
Although the exact etiology of the metabolic syndrome is not fully understood, insulin 
resistance is considered as a key factor for the development of the metabolic syndrome and 
is largely involved in the pathogenesis of individual metabolic components of the syndrome 
[49-51]. As found by the insulin-modified, frequently-sampled intravenous glucose tolerance 
assay, insulin sensitivity is significantly lower in patients with two or more than two 
components of the metabolic syndrome compared to those with none of these components 
[228-230]. It is well known that insulin plays a critical role in the regulation of glucose, 
lipid, and energy metabolism in many organs and tissues such as the liver, adipose tissue, 
muscle, heart, and gastrointestinal track [231]. Therefore, early identification of children 
and adolescents who are at risk of developing the metabolic syndrome, type 2 diabetes, and 
cardiovascular disease in later life is extremely important [232-235]. Conditions in utero and 
in early childhood could predispose a child to metabolic disorders such as obesity, insulin 
resistance, hypertension, hypercholesterolemia, hypertriglyceridemia, type 2 diabetes, 
NAFLD, NASH, cardiovascular disease, and the metabolic syndrome [236-240]. Furthermore, 
urbanization, overconsumption of nutrients, unhealthy diet, and sedentary lifestyle 
have been found to be major contributors to such disorders [241-243]. Epidemiological 
investigations have clearly shown that obesity is associated with increased risk of type 2 
diabetes and cardiovascular disease [244-246], which may persist from childhood and 
adolescence into young adulthood [247-250].
PREVENTION AND TREATMENT
Because obesity is associated with increased risk of type 2 diabetes and cardiovascular 
disease, this may continue into childhood and adolescence until adulthood. Therefore, 
lifestyle changes are the main options for the prevention of the metabolic syndrome in 
childhood and adolescence with a special focus on keeping weight within normal range 
[251,252]. Lifestyle modification includes eating healthy diet and appropriate amounts of 
total calories, increasing physical activity, and maintaining the right weight. In general, 
the therapeutic interventions are divided into (i) lifestyle modification, (ii) pharmaceutical 
therapy, and (iii) bariatric surgery [253-255].
Lifestyle modification
1. Diet
It is well known that Western diet contains high total calories, cholesterol, saturated 
fatty acids, refined carbohydrates, proteins, and salt, as well as low fibers, and it is highly 
associated with the metabolic abnormalities [256-258]. Moreover, overconsumption of 
fast foods in combination with inactive physical activity is strongly associated with the 
high prevalence of overweight, obesity, dyslipidemia, hypertension, type 2 diabetes, and 
cardiovascular disease in children and adolescents over the past 30 years [259]. Clearly, 
eating healthy diet has a significant impact on all the components of the metabolic syndrome 
[260]. Although each case should be treated individually, it is important to recommend a 
healthy diet with low total calories, cholesterol, saturated fat, and sodium, as well as high 
unsaturated fat, complex carbohydrates, and fiber [261]. This should be the first step in 
halting the development of metabolic abnormalities in children and adolescents [262-264].
It is well established that weight loss has a great benefit for the treatment of all the 
components of the metabolic syndrome, including excessive adiposity, dyslipidemia, 
hypertension, insulin resistance, and hyperglycemia [265-268]. The intensive lifestyle 
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intervention with a special focus on a significant decrease in daily caloric intake could lead 
to weight loss [269]. It is worthwhile noting that even if the magnitude of weight loss is not 
drastic, some metabolic abnormalities could be improved. As shown by the Finnish Diabetes 
Prevention Study [270], lifestyle intervention with modest weight loss could significantly 
reduce the prevalence of the metabolic syndrome compared with the control group. A modest 
weight loss often improves blood pressure regulation and decreases the risk of developing 
hypertension [271-273]. In addition, weight loss may increase plasma HDL-cholesterol 
concentrations, as well as reduce plasma triglyceride and fasting blood glucose levels, and 
hemoglobin A1c values [274-276]. A 7-day negative energy balance without measurable weight 
loss has found that reducing daily caloric intake may improve insulin sensitivity [277-279].
It has been recognized that high dietary cholesterol is a risk factor for cardiovascular disease, 
dyslipidemia, NAFLD, NASH, and cholesterol gallstone disease, with all of these being 
the major components of the metabolic syndrome [280-282]. Therefore, it is important to 
recommend a low cholesterol diet to children and adolescents. The NCEP:ATPIII guidelines 
and the recommendations from the American Heart Association and the American College 
of Cardiology have proposed a lower (<100 mg/dL) target for plasma LDL-cholesterol levels 
for individuals at high risk for adverse cardiovascular events [283-286]. Therefore, the low 
cholesterol diet could reduce not only total cholesterol concentrations in the plasma, liver, 
and bile, but also plasma LDL-cholesterol concentrations [287].
Dietary carbohydrates are often divided into two types: simple and complex. It is 
recommended that complex carbohydrates should make up most of daily carb intake [288-
290]. In contrast, simple carbohydrates, especially refined carbohydrates such as added 
sugars, should be limited [291-293]. Common sources of added sugars include soft and fruit 
drinks, as well as candies, cakes, cookies, dairy desserts, pies, and purified sugars [294-296]. 
Although chemical structures are identical between added sugars and naturally occurring 
simple sugars, e.g., sugars found in fruit, added sugars contain less or no vitamins and 
minerals. Thus, large amounts of added sugar intake could lead to a lack of nutrients found 
in foods. In addition, added sugars quickly raise blood glucose levels and increase the risk of 
insulin resistance. Based on these observations, a concept was proposed that carbohydrates 
are classified as “good” or “bad” for disease risk, as indicated by the glycemic index [297-
299]. For example, low glycemic index foods may improve components, i.e., hyperlipidemia 
and hyperglycemia, of the metabolic syndrome, whereas high glycemic index foods may 
increase the risk of insulin resistance and the metabolic syndrome [299-302]. Moreover, the 
Nurses' Health Study showed that a lower glycemic load is associated with a decreased risk of 
developing cardiovascular disease [303].
For most people, a carbohydrate intake of 45 to 65% of total daily calories is appropriate, 
as recommended by the US Department of Agriculture. In general, a diet high in complex, 
unrefined carbohydrates with an emphasis on fiber (25 g per day) and low in added sugars 
(<25% of caloric intake) is recommended for individuals with or at risk for the metabolic 
syndrome [304-307]. Clinical studies found that high daily carbohydrate intake is associated 
with increased plasma total cholesterol, LDL-cholesterol, and triglyceride concentrations, 
and reduced HDL-cholesterol levels [292,293,308-310]. In contrast, low carbohydrate 
diets may improve glucose metabolism in subjects with insulin resistance and/or type 2 
diabetes [170,311,312]. It is unclear whether low daily carbohydrate intake may influence 
lipid metabolism and reduce the risk of hypercholesterolemia and hypertriglyceridemia. 
Another explanation is that low daily carbohydrate intake may enhance insulin sensitivity, 
200https://pghn.org https://doi.org/10.5223/pghn.2020.23.3.189
Metabolic Syndrome in Children and Adolescents
thus improving cholesterol and triglyceride metabolism in the liver and plasma [30,313-315]. 
Although lower carbohydrate diets may be helpful in weight loss in the short term, the effects 
on long-term weight loss have been mixed and further studies are needed.
Most studies suggested that high fat intake, i.e., 20 to 40% of caloric intake, may increase 
the risk of overweight and obesity, thereby leading to insulin resistance. In addition, high 
fat intake may increase the prevalence of NAFLD, NASH, hypertension, type 2 diabetes, and 
cardiovascular disease [57,316-318]. However, because some conflicting results have been 
reported, it is unclear whether increased fat intake per se may have an impact on insulin 
sensitivity or may impair glucose metabolism [319]. Although the average fat intake in the 
USA has been reduced from 36.9 to 32.8% in men and from 36.1 to 32.8% in women over the 
past 50 years, there has been a marked increase in overweight, obesity, and the metabolic 
syndrome during the same time period [106,107,320]. This suggested that it may be the type 
of fats consumed, rather than the total amount of intake, producing a greater effect on the 
components of the metabolic syndrome [321,322].
The fatty acids in fat are often divided into two types: saturated and unsaturated fatty acids, 
with the latter being subclassified to monounsaturated and polyunsaturated fatty acids [57]. 
In general, saturated, but not unsaturated, fatty acids are associated with impaired glucose 
tolerance and obesity, as well as increased risk of developing NAFLD, NASH, hypertension, 
type 2 diabetes, and cardiovascular disease [323-325]. It is highly likely that a diet with high 
unsaturated fatty acids and low saturated fatty acids may improve insulin sensitivity and 
plasma lipid and lipoprotein metabolism [326]. The Nurses' Health Study has found that a 
5% increase in saturated fat intake is associated with a 17% increment in risk of coronary 
heart disease [327]. In contrast, increased monounsaturated and polyunsaturated fat intake 
may be associated with a reduced risk of coronary heart disease [328].
Low sodium intake has a good benefit for blood pressure regulation because clinical 
and epidemiological studies have revealed a clear positive relationship between sodium 
intake and blood pressure [329]. It is well known that excessive sodium intake can cause 
hypertension not only in adults, but also in children and adolescents [260]. As shown by 
the Dietary Approaches to Stop Hypertension Study [330-332], lower sodium intake reduces 
blood pressure in people with mild or moderate hypertension, as well as sodium restriction 
may be associated with decreased risk of cardiovascular disease and congestive heart failure. 
Therefore, it is strongly recommended that sodium restriction or low sodium diet should 
be given to children and adolescents, especially to obese young people. This is a key step 
for the prevention and the treatment of hypertension, a major component of the metabolic 
syndrome [333].
Because of a lack of sufficient clinical and epidemiological data, it is unclear whether 
protein intake has an association with the development of the metabolic syndrome [334]. 
A daily protein intake of 10 to 35% of total calories has been recommended for the general 
population [335]. Nevertheless, appropriate daily protein intake is good for people, 
regardless of whether they have normal weight or are obese, except for patients with 
nephropathy [336].
2. Physical activity
Epidemiological surveys have found that a sedentary lifestyle in combination with unhealthy 
eating habits likely increases the risk of insulin resistance, type 2 diabetes, cardiovascular 
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disease, NAFLD, and NASH [337]. Thus, increasing excise to reduce and/or maintain weight 
is another important approach for preventing or treating the metabolic syndrome [338-340]. 
Many epidemiological reports have shown that low physical activity is associated with increased 
prevalence of the metabolic syndrome, whereas high physical activity is likely to protect against 
the development of the metabolic syndrome [341]. Indeed, higher cardiorespiratory fitness 
and extensive physical activity have been shown to improve glucose metabolism and insulin 
sensitivity and reduce cardiovascular disease mortality, as well as the risk of type 2 diabetes, 
NAFLD, and NASH [342-345]. It is likely that increasing physical activity could reduce the risk 
of cardiovascular disease and the prevalence of type 2 diabetes, NAFLD, and NASH through 
weight loss [346-348]. Furthermore, cardiorespiratory fitness and intensive physical activity 
prevent the development of the metabolic syndrome likely through their effects on each of 
the individual components [343,349,350]. Clinical studies have revealed that combining 
with healthy dietary intake, high-intensity exercise, i.e., aerobic exercise, is very effective at 
enhancing insulin sensitivity and reducing weight, particularly abdominal adiposity, as well as 
potentially improving hypertension, hyperglycemia, and dyslipidemia [351-354].
As shown by a systematic review of the literature, aerobic exercise may reduce visceral 
adiposity in a dose-dependent manner [355-357]. However, it is unclear whether exercise 
could reduce visceral adipose tissue in the absence of weight loss [358]. To achieve continued 
benefit of exercise on insulin action, the American Heart Association and the American 
College of Sports Medicine have recommended exercise at least 30 minutes/day most days 
of the week [359]. Aerobic exercise may produce a persistent effect on glucose tolerance 
and insulin action beyond the immediate post-exercise effects and possibly through weight 
loss [360-362]. More importantly, while maintaining weight, regular aerobic exercise is still 
critical to reducing abdominal fat tissue and preventing weight regain in individuals who 
have successfully lost weight [362-364].
Pharmaceutical therapy
Because there are no published papers reporting double-blind, randomized controlled trials 
on the management of the metabolic syndrome, no guidelines or specific recommendations 
are currently available for treating the metabolic syndrome [365-371]. In addition, because the 
cellular and molecular mechanisms underlying the pathogenesis of the metabolic syndrome 
are not completely understood, the therapeutic options have not yet been developed [10]. The 
currently available therapeutic strategies focus mainly on treating the individual components 
of the metabolic syndrome, with the overall goals of reducing the risk of cardiovascular 
disease and type 2 diabetes or preventing them [86,372-376] Moreover, some therapeutic 
options may have a marked impact on two or more than two components of the metabolic 
syndrome [377-379]. Nevertheless, many therapeutic efforts on the treatment of the visceral 
obesity and insulin resistance associated with the metabolic syndrome may provide the most 
overall success in achieving these goals [380-387].
Bariatric surgery
For adults, if a body mass index (BMI) is ≥40 or a BMI is 35 in patients with significant 
obesity-related comorbidities, bariatric surgery can be considered as a weight loss procedure 
[388-392]. Because of a lack of clear evidence concerning surgical treatment for children 
and adolescents, bariatric surgery is not recommended by the NIH Consensus Panel as an 
acceptable alternative that can achieve sustained weight loss in young patients [393-396]. 
However, when lifestyle modification and standard pharmaceutical therapy are not effective 
in reducing body weight and BMI, bariatric surgery may be considered for children and 
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adolescents [397-400]. In general, the surgical interventions include Roux-en-Y gastric 
bypass (RYGBP), adjustable gastric band, sleeve gastrectomy, and biliopancreatic diversions 
for obese children and adolescents [401-408]. The limited experience with bariatric surgery 
in young patients suggests that RYGBP surgery and adjustable gastric banding can effectively 
treat the comorbidities of adolescent obesity. The surgery can be open and/or laparoscopic 
procedures [409]. However, because children and adolescents are still developing, both 
physically and mentally, they and/or their parents may show less willingness to give consent 
to surgery [410]. Moreover, bariatric surgery may dramatically change their lives after 
operation. Therefore, careful consideration must be given to whether or not surgery is 
performed on obese children and adolescents [411-414]. Table 5 [404] lists indications and 
contraindications for bariatric surgery in children and adolescents.
As shown in the data from the US National Inpatient Sample, 2,744 adolescents have 
received bariatric surgeries in the USA from 1996 to 2003 [415]. Because many children and 
adolescents with clinically severe obesity are interested in a bariatric surgical option to attain 
a healthier weight, it is estimated that more and more bariatric operations have been done 
since this time [415]. Similar to adults, bariatric surgery leads to very good short-term weight 
outcomes in children and adolescents [415]. Among different surgical methods, RYGB 
produces the greatest weight loss, as shown by the most reliable clinical evidence [416-419]. 
Because no other evidence-based medical interventions lead to a similar magnitude of weight 
loss, bariatric surgery could be considered a treatment option especially for children and 
adolescents who have obesity-related complications and comorbidities [420-423].
Although there are compelling reasons to offer bariatric procedures to some children and 
adolescents in whom prior weight management attempts have not been successful [424-
429], there are also disagreements and dissenting voices because of the limited experience 
with bariatric surgery in young patients. Furthermore, children and adolescents can lose 
weight more effectively with lifestyle modification compared to adults, but they have not 
always made their best attempts at nonsurgical weight loss [430-432]. More aggressive 
steps should be taken to improve young people's lifestyles to achieve sustained weight loss. 
In addition, children and adolescents are still growing with age, which could be adversely 
affected by nutritional consequences of a bariatric operation [433-435]. Although many 
seriously obese adolescents are interested in bariatric procedures to achieve weight loss, 
they are not psychologically prepared for bariatric surgery [436]. Therefore, it is necessary 
to propose more strict bariatric surgery standards for young people compared to adults 
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Table 5. Indications and contraindications for bariatric surgery in children and adolescents
Indications:
· Failure of at least 6 months of organized, medically supervised weight loss attempts
· Ages 13 to 18 for girls, and 14 to 18 for boys
· BMI ≥40 with presence of severe obesity-related comorbidity
· BMI ≥50 with less severe obesity-related comorbidities
Contraindications:
· Substance abuse problem within the preceding year
·  Psychiatric diagnosis that would impair ability to adhere to postoperative dietary or medication regimen 
(e.g., psychosis)
· Medically correctable cause of obesity
·  Inability or unwillingness of patient or parent to fully comprehend the surgical procedure and its medical 
consequences
· Inability or refusal to participate in lifelong medical surveillance
BMI: body mass index.
Modified and reproduced with permission from reference [404].
[404]. In addition, to more carefully evaluate the harms and benefits of bariatric surgery 
for children and adolescents, it is imperative to perform long-term, prospectively designed 
clinical studies, with clear inclusion and exclusion criteria and reporting of beneficial effects, 
side effects, complications, and comorbidity resolution, as well as measures of health-related 
quality of life after operation [437].
CONCLUSIONS AND FUTURE DIRECTIONS
Clearly, the metabolic syndrome, by definition, is not a disease but is a clustering of 
individual metabolic risk factors that could dramatically increase the prevalence of type 2 
diabetes and cardiovascular disease. Although many definitions of the metabolic syndrome 
in children and adolescents have been proposed, no unified definition exists to assess risk 
or outcomes in pubertal subjects to date. Because dysfunctional glucose, lipid, and energy 
metabolism across several organs and tissues occurs under insulin resistant conditions, 
together creating the observed interplay of several concurrent metabolic abnormalities, 
early identification of children and adolescents at risk of developing the metabolic syndrome 
is extremely important. A clinically accessible diagnostic tool is needed to identify the 
metabolic syndrome in young people globally. This will greatly prompt the development of a 
new simple definition that is easy to apply for clinical practice and epidemiological surveys.
For future research, it is imperative to decipher the relationship between body fat and its 
distribution in the body in children and adolescents and investigate whether early growth 
patterns predict future adiposity and other features of the metabolic syndrome. More 
importantly, it is urgent to perform long-term cohort studies on children and adolescents of 
different ethnic origin into adulthood by investigating the natural history and effectiveness 
of interventions, especially those related to lifestyle. As indicated in Fig. 3, early detection 
followed by treatment, particularly lifestyle intervention, is vital to halt the progression of 
the metabolic syndrome in children and adolescents. Such an action should reduce morbidity 
and mortality in adulthood and help minimize the global burden of cardiovascular disease 
and type 2 diabetes.
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Exercise
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Fig. 3. Because obesity is associated with increased risk of type 2 diabetes and cardiovascular disease, this 
may continue into childhood and adolescence until adulthood. Therefore, lifestyle modifications, including 
eating healthy diet and appropriate amounts of total calories, increasing physical activity, and maintaining the 
right weight, are the main options for the prevention of the metabolic syndrome by halting the development of 
metabolic abnormalities in childhood and adolescence.
Lifestyle interventions and other non-pharmacological treatments are often considered to 
be the first option but, such interventions have variable outcomes. Eating healthy diet and 
appropriate amounts of total calories, increasing physical activity, and maintaining the right 
weight could substantially improve insulin resistance, blood pressure, and plasma lipid and 
lipoprotein metabolism. Pharmacological treatment appears to have modest effectiveness. 
However, when combined with lifestyle interventions, it is associated with more adverse 
effects than lifestyle interventions alone. Several surgical procedures are available for 
children and adolescents; however, long-term effects of bariatric surgery from high quality 
studies are strongly needed.
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